Storkhead box 2 and melanoma inhibitory activity promote oral squamous cell carcinoma progression
-
- Tomonori Sasahira
- Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
-
- Yukiko Nishiguchi
- Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
-
- Rina Fujiwara
- Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
-
- Miyako Kurihara
- Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
-
- Tadaaki Kirita
- Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan
-
- Anja Katrin Bosserhoff
- Institute of Biochemistry, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
-
- Hiroki Kuniyasu
- Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
書誌事項
- 公開日
- 2016-03-30
- 資源種別
- journal article
- DOI
-
- 10.18632/oncotarget.8495
- 公開者
- Impact Journals, LLC
説明
Storkhead box protein 2 (STOX2) is a transcriptional factor associated with pre-eclampsia with fetal growth restriction. We recently reported that melanoma inhibitory activity (MIA) promotes oral squamous cell carcinoma (OSCC) progression. However, the relationship between STOX2 and MIA remains unknown in malignancies.We used immunohistochemistry and PCR to investigate MIA and STOX2 expression in OSCC. We also performed functional analysis in human OSCC cells.MIA and STOX2 mRNA levels were higher in OSCCs than in normal oral epithelial cells, and upregulation of STOX2 was significantly correlated with overexpression of MIA. Immunostaining for STOX2 was associated with nodal metastasis (P = 0.0002) and MIA expression (P < 0.0001). Furthermore, MIA expression (P = 0.0035) and STOX2 expression (P = 0.0061) were associated with poor outcome in OSCCs. In vitro analysis using OSCC cells revealed that MIA increased expression of STOX2 by paracrine manner. Moreover, STOX2 accelerated OSCC cell growth, invasion, suppressed apoptosis, and enhanced resistance to paclitaxel, cisplatin, and 5-FU.Our results suggest that MIA-STOX2 signaling may be a useful diagnostic and therapeutic target in OSCCs.
収録刊行物
-
- Oncotarget
-
Oncotarget 7 (18), 26751-26764, 2016-03-30
Impact Journals, LLC
- Tweet
キーワード
- Adult
- Male
- Extracellular Matrix Proteins
- Squamous Cell Carcinoma of Head and Neck
- Kaplan-Meier Estimate
- Middle Aged
- Disease-Free Survival
- Neoplasm Proteins
- Head and Neck Neoplasms
- Biomarkers, Tumor
- Carcinoma, Squamous Cell
- Disease Progression
- Humans
- Female
- Mouth Neoplasms
- Carrier Proteins
- Research Paper
- Aged
- Proportional Hazards Models
詳細情報 詳細情報について
-
- CRID
- 1360004238274347776
-
- ISSN
- 19492553
-
- PubMed
- 27050375
-
- 資料種別
- journal article
-
- データソース種別
-
- Crossref
- KAKEN
- OpenAIRE